MDGL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.85%, SMA50 -13.21%, SMA200 4.95%). The stock’s 14-day RSI is 38.48 (weak momentum), while the ATR of 22.33 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -27.5% below its high and over 68.25% above its low. Average 10-day trading volume of 315.20 thousand shares is in line with the 3-month average of 331.93 thousand, indicating normal recent market interest.

Madrigal Pharmaceuticals, Inc. has 22.29 million shares outstanding. The public float is 11.01 million shares, elevated short interest at 20.76% of float. This equals 3.98 million shares. The short ratio is 11.26 days. Institutional investors hold 116.89% of the float. Insiders own 7.67%. Taub Rebecca holds 452.21 thousand shares, CRAVES FRED B has 350.08 thousand shares and BAKER BROS. ADVISORS LP has 198.24 thousand shares. Over the past six months, insider transactions show net selling. They sold 13.05 thousand shares across 20 transactions.

Madrigal Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $173.94. This means the shares are trading above this model’s fair value.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) closed at $451.49 USD, gaining $10.32 (2.34%) from the previous close of $441.16. The stock is currently mid-range between its 52-week high and low $265.00 and $615.00. With a market capitalization of about $10.36 billion, Madrigal Pharmaceuticals, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~-0.96). Key stats such as the average daily volume over the past year has been around 344.89 thousand shares, volume is running light vs its 52-week average. Headquartered in West Conshohocken, PA, Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William J. Sibold, the company employs approximately 528 people and listed since February 06, 2007. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

Our AI price prediction model suggests that Madrigal Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.1%, with price expected at $446.03 by April 03, 2026, within a range of $432.43 to $458.94 3-Month Outlook: Projected fall of -48.58%, reaching $226.84 by June 18, 2026, with a range of $216.19 to $238.01. 1-Year Outlook: Projected gain of 21.21%, with price at $534.75 by March 19, 2027, within a range of $511.66 to $562.30.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares are down -13.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Madrigal Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -34.33. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $375.42, suggesting -14.9% downside. Our AI forecast model points to short-term strength (1.1% over two weeks), a medium-term fall (-48.58% over three months), and a longer-term gain (21.21% over one year), with expected trading ranges indicating moderate volatility.

Madrigal Pharmaceuticals, Inc. generated EPS of -$12.86 over the past year. Five-year average earnings growth is 0.37%. The latest quarter delivered EPS of -$5.08. The next quarter is forecast at -$3.68. Next year's EPS is expected at $14.03. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 13 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $964.00 to $428.00. The high target offers 118.51% upside. The low target suggests -2.98% downside. The mean target is $592.61. This offers 34.33% upside. Madrigal Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by 149.38%. The prior quarter beat by -45.4%. Over the last six quarters, Apple has recorded several small beats. These include -5.95% in August 07, 2024.

Madrigal Pharmaceuticals, Inc. trades at a P/E ratio of -34.33, slightly below the S&P 500 average, with a price-to-sales ratio of 10.56 and a price-to-book ratio of 16.42 reflecting a rich premium to book value. The P/FCF stands at -53.26, also below market averages. Compared to sector medians, Madrigal Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.